One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
IDEXX Laboratories logo
IDEXX Laboratories IDXX
$ 675.24 -2.1%
report update icon

Quarterly report 2026-Q3
added 11-02-2026

IDEXX Laboratories Financial Ratios 2025-2007 | IDXX

Brief overview of IDEXX Laboratories's financial ratios

Ratios are assessed across five available annual reports in the 2021–2025 interval.

The latest available valuation ratios are P/E 48.25x (median 56.14x), EV/EBITDA 45.27x (median 39.53x), P/S 11.88x (median 12.7x). Current valuation broadly matches recent historical reference points; the difference from five-year medians is -6.5%.

Current earnings relative to valuation equal about 2.1% on the 1/P/E measure. This is a valuation reference, not an expected payout.

The latest available business-quality ratios are ROE 66%, ROA 31.6%, ROCE 61.8%. Profitability forms a strong profile, with capital and assets producing substantial returns.

Current PEG of 3.06x points to a premium over forecast earnings momentum.

The cash conversion cycle lengthened from 90.5 days to 102.9 days, or 12.4 days. More cash is tied up in operations.

What the ratios show

IDEXX Laboratories's market valuation is near its own historical norm, while quality ratios provide no extreme signal.

Annual Financial Ratios IDEXX Laboratories

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
48.3 42.4 56.1 63.0 60.9 76.3 57.1 47.8 62.2 48.7 33.8 43.6 32.2 29.7 29.7 12.7 10.5 12.9 -

P/S

11.9 9.7 13.0 12.7 14.1 16.4 10.2 8.2 8.3 6.1 4.1 5.3 4.4 4.1 3.9 - - - -

EPS

13.2 10.8 10.2 8.1 8.7 6.8 5.0 4.3 3 2.5 2.1 1.8 1.8 3.2 2.9 2.5 2.1 1.9 -

EV (Enterprise Value)

52.7 B 39.1 B 48.8 B 44.8 B 47 B 45.7 B 26 B 19.5 B 18 B 12.3 B 7.93 B 8.87 B 6.48 B 5.53 B 5.12 B 1.96 B 1.48 B 1.42 B -60.4 M

EBITDA per Share

18.7 15.3 14.6 12.1 12.2 9.26 7.44 6.61 5.65 4.77 4.07 3.19 3.02 2.86 2.5 4.33 3.84 3.68 -

EV/EBITDA

35.0 31.0 40.2 44.3 45.3 57.8 39.5 32.9 35.2 27.7 20.0 26.6 18.4 16.1 16.3 7.9 6.5 6.4 -

PEG

3.06 2.64 3.18 3.72 2.93 4.26 3.94 1.07 2.9 2.52 2.41 15.39 3.6 2.17 1.82 - - - -

P/B

31.8 23.6 32.0 70.3 65.7 70.2 137.4 -1953.9 -304.2 -99.9 -77.3 67.4 11.7 8.3 8.9 3.1 2.5 - -

P/CF

43.3 40.5 52.3 78.8 60.0 68.5 80.4 65.1 55.2 40.1 48.7 45.3 36.1 32.3 28.8 10.1 7.4 10.4 -

ROE %

65.99 55.65 56.92 111.56 107.95 92.04 240.53 -4083.52 -488.73 -205.19 -228.68 154.70 36.24 28.02 29.98 24.60 23.75 26.51 -

ROA %

31.62 26.96 25.92 24.72 30.56 25.35 23.34 24.52 15.36 14.51 13.02 13.14 15.26 16.15 15.69 15.75 15.12 - -

ROCE %

61.76 50.70 47.53 59.48 55.69 40.59 49.93 64.07 58.27 58.75 49.84 46.20 35.47 37.66 39.77 33.31 31.87 39.36 -

Current Ratio

1.9 1.9 1.8 1.3 1.4 1.4 0.9 0.8 1.0 0.9 1.0 0.9 1.4 1.4 1.2 2.8 2.8 - -

DSO

43.5 43.6 42.8 41.7 39.7 40.5 46.6 45.0 50.1 47.7 45.6 44.5 41.9 39.0 42.3 - - - -

DIO

84.3 91.6 92.8 85.3 65.9 65.1 68.4 65.1 68.8 72.1 96.9 87.4 78.4 86.6 84.9 82.9 - - -

DPO

24.9 27.0 27.4 23.4 26.2 23.6 25.3 26.1 28.0 27.4 27.0 24.4 17.6 21.7 23.3 14.5 6.9 - -

Operating Cycle

127.8 135.2 135.6 127.0 105.6 105.6 115.0 110.1 118.9 119.8 142.5 131.9 120.3 125.6 127.2 82.9 - - -

Cash Conversion Cycle

102.9 108.2 108.2 103.6 79.4 82.0 89.7 83.9 90.8 92.4 115.4 107.5 102.7 103.9 103.9 68.3 - - -

All numbers in USD currency

Quarterly Financial Ratios IDEXX Laboratories

2026-Q3 2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1 2010-Q4 2010-Q3 2010-Q2

EPS

4.02 4.29 3.5 3.1099999999999994 3.43 3.66 2.98 2.6500000000000004 2.83 2.46 2.84 2.34 2.55 2.7 2.58 2.079999999999999 2.17 1.57 2.3 1.92 2.06 2.37 2.39 2.0500000000000007 1.71 1.75 1.31 1.05 1.26 1.46 1.19 0.99 1.07 1.25 1.02 0.44 0.81 0.97 0.78 0.59 0.63 0.75 0.51 0.49 0.48 0.61 0.49 0.27 0.52 0.56 0.45 0.83 0.87 1.01 0.82 0.79 0.78 0.93 0.74 0.68 0.68 0.85 0.64 0.63 0.6 0.64

EBITDA per Share

5.1 6.39 5.03 -1.77 K 4.89 4.64 4.31 -1.26 K 4.11 3.19 3.96 21.7 K 3.66 3.9 3.72 -683 3.28 2.47 3.26 -1.08 K 2.97 3.34 3.19 2.52 2.3 2.55 1.96 -655 1.88 2.16 1.79 1.34 2.07 1.91 1.53 -393 1.38 1.63 1.28 -237 1.2 1.38 1.03 -44 0.98 1.13 0.94 -0.64 0.88 0.96 1.62 0.57 1.51 1.73 1.37 -390 1.38 1.61 1.32 -81.5 1.2 1.45 1.13 -591 1.06 1.34

ROE %

71.31 71.93 71.10 69.96 68.05 64.85 57.56 55.82 55.37 57.34 64.98 75.41 90.60 112.25 120.63 125.50 120.80 105.97 104.17 102.90 106.96 116.94 144.36 218.83 242.08 262.59 281.37 375.87 -602.55 -1636.48 -1975.81 -2356.49 -1500.02 -665.49 -498.63 -409.39 -386.73 -138.35 -830.01 -798.95 -803.35 -1020.00 436.71 635.76 710.63 847.35 194.12 66.54 52.81 38.62 35.81 33.82 32.29 30.69 29.56 29.64 29.87 29.50 28.79 27.74 27.03 26.81 25.91 6.33 6.35 7.09

ROA %

34.02 33.57 32.57 31.89 31.05 29.89 27.02 26.49 25.89 25.82 27.68 28.28 28.58 28.56 25.81 25.67 26.08 26.56 29.90 31.20 32.14 31.95 31.15 28.30 25.61 24.68 24.37 24.55 25.18 25.04 24.89 24.87 21.53 19.69 17.76 16.07 17.25 16.79 16.09 14.81 14.39 13.63 12.97 13.11 11.98 13.03 13.63 14.07 15.71 15.49 15.67 15.94 16.35 16.45 16.62 16.50 16.26 16.31 16.62 16.80 17.17 17.22 16.57 4.05 4.03 4.46

ROCE %

67.94 68.09 66.04 63.90 61.32 57.68 51.45 48.69 47.56 47.59 51.01 54.63 58.99 62.87 60.39 59.62 56.53 52.55 54.84 54.04 52.95 51.35 50.23 49.60 49.23 50.36 51.61 51.16 55.76 58.64 63.28 65.12 63.88 63.49 63.27 62.51 62.77 59.80 56.15 53.94 50.70 49.77 46.72 46.02 41.38 41.29 40.90 38.70 40.67 40.61 41.29 40.72 41.66 40.07 38.91 39.76 39.98 39.56 38.79 37.51 36.50 36.06 34.88 8.30 8.42 9.75

Current Ratio

2.0 1.9 1.9 1.9 1.9 1.8 1.8 1.9 1.9 1.9 1.9 1.8 1.7 1.6 1.4 1.3 1.2 1.2 1.3 1.4 1.5 1.4 1.4 1.4 1.3 1.2 1.1 1.1 1.1 1.1 1.0 1.0 1.0 1.0 1.0 1.0 1.0 0.9 1.0 0.9 1.0 1.0 0.9 0.9 1.0 1.0 1.0 1.1 1.2 1.6 1.7 1.7 1.8 1.9 2.3 2.4 2.3 2.2 2.1 2.1 2.5 2.8 2.9 2.8 2.7 2.7

DSO

46.7 46.1 46.2 46.8 46.5 44.7 45.7 47.1 48.9 47.3 45.6 46.1 45.6 43.9 42.9 43.4 43.4 43.2 42.0 42.4 42.7 42.2 41.8 42.3 41.6 44.4 41.5 40.5 41.8 41.7 42.0 41.3 43.0 41.2 42.0 41.7 43.4 41.7 42.5 42.1 42.4 41.5 43.8 43.3 43.8 43.7 41.6 40.5 39.1 40.8 42.8 39.9 41.9 41.2 40.8 39.9 41.7 41.9 42.7 41.0 43.1 41.2 40.2 - - -

DIO

79.3 80.7 83.0 81.2 84.8 86.8 94.6 91.8 92.5 91.5 94.8 94.1 98.0 96.7 96.9 96.0 93.6 83.5 77.1 69.8 67.6 63.2 64.7 62.6 68.2 77.9 69.6 66.5 70.4 67.2 67.7 - 66.5 65.3 66.8 66.6 72.5 72.1 73.9 73.6 77.9 79.6 89.5 95.6 94.4 90.4 91.2 85.0 80.8 76.2 79.2 77.1 85.8 85.2 89.1 87.4 91.7 86.1 84.6 83.1 86.9 82.8 84.4 85.2 90.8 -

DPO

28.7 27.0 26.2 24.6 25.8 26.0 20.6 19.0 27.4 27.9 21.7 20.8 27.3 27.7 22.6 22.5 32.3 32.7 25.0 20.0 24.3 24.4 19.7 17.2 22.2 26.2 19.4 19.1 25.1 24.0 20.8 - 26.2 25.4 20.9 19.1 24.9 25.5 21.2 17.3 21.3 22.7 19.8 21.0 28.0 25.9 17.9 21.4 26.7 22.4 21.0 18.8 22.6 22.5 22.8 20.3 19.4 21.2 23.8 20.8 19.5 16.9 15.2 15.7 17.4 -

Operating Cycle

126.0 - 129.2 128.0 131.3 131.5 140.4 138.9 141.4 138.8 140.4 140.2 143.5 140.6 139.8 139.4 137.1 126.7 119.1 112.3 110.3 105.5 106.6 105.0 109.8 122.3 111.0 107.0 112.2 109.0 109.7 41.3 107.6 106.6 108.8 108.3 116.0 113.9 116.4 115.8 120.3 121.1 133.2 138.9 138.2 134.1 132.8 125.6 120.0 116.9 122.0 117.0 127.7 126.3 129.9 127.4 133.4 128.0 127.3 124.2 130.0 124.0 124.6 85.2 90.8 -

Cash Conversion Cycle

97.3 - 103.0 103.4 105.5 105.5 111.9 119.9 114.0 110.9 112.4 119.3 116.2 112.9 117.2 116.9 104.7 94.0 94.1 92.3 86.0 81.0 86.8 87.7 87.5 96.1 91.6 87.9 87.1 85.0 88.9 41.3 81.1 81.1 87.8 89.2 91.0 88.4 95.1 98.4 99.0 98.4 113.4 117.9 110.2 108.2 114.9 104.2 93.2 94.5 101.0 98.2 105.1 103.9 107.1 107.1 114.1 106.7 103.5 103.4 110.5 107.1 109.4 69.4 73.5 -

All numbers in USD currency

Multiples are an important financial analysis tool for the company IDEXX Laboratories, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
T2 Biosystems T2 Biosystems
TTOO
- -39.35 % $ 313 K usaUSA
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Brainsway Ltd. Brainsway Ltd.
BWAY
$ 8.53 -2.29 % $ 290 M israelIsrael
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 13.46 1.05 % $ 142 M chinaChina
Medpace Holdings Medpace Holdings
MEDP
$ 609.81 -3.81 % $ 17.6 B usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
RadNet RadNet
RDNT
$ 69.77 0.37 % $ 5.25 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
Biodesix Biodesix
BDSX
$ 7.55 -9.1 % $ 57 M usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Agilent Technologies Agilent Technologies
A
$ 169.82 -3.21 % $ 48.2 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 314.38 -4.13 % $ 15.6 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 257.78 -0.4 % $ 28.6 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 220.3 -3.19 % $ 157 B usaUSA
DexCom DexCom
DXCM
$ 79.02 -1.46 % $ 30.8 B usaUSA
Anixa Biosciences Anixa Biosciences
ANIX
$ 2.44 -6.15 % $ 79.2 K usaUSA
Celcuity Celcuity
CELC
$ 53.32 -5.31 % $ 2.49 B usaUSA
Guardant Health Guardant Health
GH
$ 145.9 0.21 % $ 18.3 B usaUSA
BioNano Genomics BioNano Genomics
BNGO
$ 0.82 -7.56 % $ 4.46 M usaUSA
Bioventus Bioventus
BVS
$ 9.89 -0.65 % $ 659 M usaUSA
IQVIA Holdings IQVIA Holdings
IQV
$ 245.67 -1.92 % $ 42.2 B usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 367.68 -0.44 % $ 30.6 B usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 32.69 -2.14 % $ 948 M usaUSA
Mettler-Toledo International Mettler-Toledo International
MTD
$ 1 667.59 -2.3 % $ 34.4 B schweizSchweiz
Illumina Illumina
ILMN
$ 192.79 -3.92 % $ 29.9 B usaUSA
Natera Natera
NTRA
$ 273.11 -5.8 % $ 37.3 B usaUSA
Koninklijke Philips N.V. Koninklijke Philips N.V.
PHG
$ 28.63 -2.22 % $ 27.1 B niderlandNiderland
Fulgent Genetics Fulgent Genetics
FLGT
$ 24.03 -3.03 % $ 740 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 69.9 -2.81 % $ 3.72 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
Biomerica Biomerica
BMRA
$ 1.09 -0.46 % $ 3.18 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 4.4 -4.35 % $ 19.5 M usaUSA
Lantheus Holdings Lantheus Holdings
LNTH
$ 102.12 0.01 % $ 6.89 B usaUSA
Senseonics Holdings Senseonics Holdings
SENS
$ 8.03 -9.88 % $ 335 M usaUSA
Sotera Health Company Sotera Health Company
SHC
$ 15.92 -1.82 % $ 4.52 B usaUSA
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
ICON Public Limited Company ICON Public Limited Company
ICLR
$ 186.79 -1.88 % $ 14.6 B irlandaIrlanda